NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE American · Medical Instruments & Supplies · USD

Stereotaxis, Inc. (STXS) Stock Analysis

Stereotaxis, Inc. (STXS) is a Medical Instruments & Supplies stock listed on NYSE American and quoted in US Dollar.

Last Updated: October 21, 2026

STXS

$0.99

−$0.00 (−0.34%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare STXS with… →

STXS Key Statistics

As of Oct 21, 2026
Trading
Open
$0.99
Previous Close
$1.00
Day's Range
0.98–1.04
52-Week Range
0.95–3.15
Volume
615.27K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.37
Valuation
Market Cap
$99.69M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.31
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.32
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.24
Financials (FY)
Revenue (FY)
$32.38M+20.28%
Net Income (FY)
−$21.64M
Profit marginThe share of revenue left as profit after all costs and taxes.
−74.24%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
100.20M
1-Year Return
−67.38%
Dividend and dates
Earnings Date
November 10, 2026
Avg Volume
639.70K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, STXS closed at $0.99, −67.38% over 1 year.

Stereotaxis, Inc. (STXS) has a market capitalization of $99.69M.

In fiscal 2025, STXS reported revenue of $32.38M.

STXS Stock Return by Calendar Year

Stereotaxis, Inc. (STXS) 10-year return: what $10,000 became

1 year
$10,000 $3,262
−67.38%
5 years
$10,000 $1,634
−83.66%
10 years
$10,000 $13,265
+32.65%

If you had invested $10,000 in Stereotaxis, Inc. (STXS) 10 years ago, at the close on October 21, 2016, it would have been worth $13,265 at the close on October 21, 2026: +32.65% in total, +2.87% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−56.74%
2025+0.88%
2024+30.29%
2023−15.46%
2022−66.61%
2021+21.81%
2020−3.78%
2019+389.81%
2018+35.00%
2017+23.08%
2016 (partial year)−12.16%

As of October 21, 2026.

STXS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$32.38M−$21.64M−66.8%
2024$26.92M−$24.05M−89.3%
2023$26.77M−$20.71M−77.4%
2022$28.15M−$18.29M−65.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$32.38M$17.07M−$22.11M−$21.64M−66.8%
2024$26.92M$14.59M−$24.74M−$24.05M−89.3%
2023$26.77M$14.86M−$21.84M−$20.71M−77.4%
2022$28.15M$18.47M−$18.78M−$18.29M−65.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

STXS Valuation vs Medical Instruments & Supplies Median

Median of 50 stocks
MetricSTXSMedical Instruments & Supplies medianvs median
P/S ratio3.322.6028% above
Profit margin−74.24%1.62%75.9 pts below

Medians across 50 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Stereotaxis, Inc. (STXS) is capitalised at $99.69M on the latest close. The company sits in the Healthcare sector, in the Medical Instruments & Supplies industry. The company reports 131 employees.

Over the past 52 weeks the price has ranged from $0.95 to $3.15. STXS last closed at $0.99 on October 21, 2026. That is $0.00 (−0.34%) against the previous close. The latest close sits 4.73% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $32.38M. That is +20.28% against the prior fiscal year, when revenue was $26.92M. The same year closed with a net loss of $21.64M. Profit margin runs at −74.24%. That is 75.9 percentage points below the Medical Instruments & Supplies median of 1.62%. Earnings per share on a trailing basis come to −0.24.

Across the 4 fiscal years on file, revenue moves from $28.15M in 2022 to $32.38M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.31. The price-to-sales ratio is 3.32. On price-to-sales that is 27.63% above the Medical Instruments & Supplies median of 2.6. The medians here are taken across 50 Medical Instruments & Supplies companies that report the metric.

The trailing one-year total return is −67.38%. Measured over 10 years, that is +2.87% a year compounded. Beta against the wider market is reported at 1.37. Annualized volatility over the trailing 10 years is 71.78%.

Growth & Income

No dividend is on file for STXS.

2026 is still running; the total return is −56.74% year to date. The strongest complete calendar year on file is 2019 at +389.81%; the weakest is 2022 at −66.61%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Stereotaxis, Inc. (STXS) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Stereotaxis, Inc. STXS $99.69M —
Intuitive Surgical, Inc. ISRG $151.25B 51.8
Becton, Dickinson and Company BDX $52.79B 45.1
Medline Inc. MDLN $47.51B 88.3

The Medical Instruments & Supplies industry average P/E ratio is 31.2x. Stereotaxis, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Instruments & Supplies Stocks

ISRG

Intuitive Surgical, Inc.

$151.25B

 BDX

Becton, Dickinson and Company

$52.79B

 MDLN

Medline Inc.

$47.51B

 RMD

ResMed Inc.

$34.63B

 ALC

Alcon Inc.

$32.60B

 WST

West Pharmaceutical Services, Inc.

$27.69B
View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Stereotaxis, Inc.

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Navigation by reducing the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a Synchrony and SynX Solution offer integrated, real-time information solution to manage, control, record and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including MAGiC catheter, a robotically navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures; MAGiC Sweep, a mapping catheter; QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; and V-CAS devices. Further, it provides interventional devices under the Map-iT, MAGiC, and EMAGIN brands, and other related devices. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.

Visit website →